Treatment as Prevention¨

Icelandic HCV elimination program treats majority of viremic population

Since its launch in 2016, a hepatitis C elimination program in Iceland has treated approximately 56% to 70% of the estimated viremic population with direct-acting antivirals, according to a recently published update. “The idea was to offer DAAs to all HCV-positive patients within an entire population within a relatively short time frame and simultaneously initiate

Icelandic HCV elimination program treats majority of viremic population Read More »

A shift over time in the HIV ward of one of Canada’s largest hospitals

Numerous studies have found that the use of potent combination anti-HIV therapy (ART) strengthens the immune system and overall health. ART does this by gradually reducing the amount of HIV produced to very low levels-commonly called “undetectable.” This then allows the immune system to partially repair itself. The benefit of ART is so profound that

A shift over time in the HIV ward of one of Canada’s largest hospitals Read More »

Diabetes in people with HIV over 50 overwhelmingly linked to old antiretrovirals, not age or body weight

People with HIV over the age of 50 are more likely to have developed type 2 diabetes if they started antiretroviral treatment before 1999 or had a longer exposure to older antiretroviral drugs such as stavudine (d4T) or first-generation protease inhibitors such as nelfinavir or indinavir, according to a study of people receiving HIV care

Diabetes in people with HIV over 50 overwhelmingly linked to old antiretrovirals, not age or body weight Read More »

Scroll to Top

The British Columbia Centre for Excellence in HIV/AIDS Laboratory has discontinued gp-41 resistance testing as T-20 (enfuvirtide/Fuzeon) is no longer available in Canada as of March 31, 2025